Idera Pharmaceuticals Inc. [NASDAQ: IDRA] jumped around 0.67 points on Friday, while shares priced at $4.26 at the close of the session, up 18.66%. The company report on November 18, 2020 that Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer.
– COO Role is Key to Preparedness for NDA Filing and Commercial Launch –– Clayton Fletcher, Head of Business Development & Strategic Planning, to Retire –.
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; “Idera”) announced that Daniel Soland will join Idera on January 4, 2021, as Senior Vice President and Chief Operating Officer (COO). Mr. Soland has been engaged as a consultant to Idera for nearly three years. In his role as COO, he will be responsible for commercial strategy and manufacturing as Idera plans for success in anticipation of data from its pivotal trial, ILLUMINATE-301, which are currently expected in the first quarter of 2021.
Idera Pharmaceuticals Inc. stock is now 134.07% up from its year-to-date (YTD) trading value. IDRA Stock saw the intraday high of $4.90 and lowest of $3.59 per share. The company’s 52-week high price is 3.70, which means current price is +423.99% above from all time high which was touched on 11/20/20.
Compared to the average trading volume of 251.79K shares, IDRA reached a trading volume of 1851763 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Idera Pharmaceuticals Inc. [IDRA]?
Barclays have made an estimate for Idera Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 24, 2018. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on August 15, 2018, representing the official price target for Idera Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $4, while H.C. Wainwright analysts kept a Buy rating on IDRA stock.
The Average True Range (ATR) for Idera Pharmaceuticals Inc. is set at 0.34
How has IDRA stock performed recently?
Idera Pharmaceuticals Inc. [IDRA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 50.00. With this latest performance, IDRA shares gained by 100.00% in over the last four-week period, additionally plugging by 134.07% over the last 6 months – not to mention a rise of 131.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IDRA stock in for the last two-week period is set at 81.12, with the RSI for the last a single of trading hit 85.50, and the three-weeks RSI is set at 76.12 for Idera Pharmaceuticals Inc. [IDRA]. The present Moving Average for the last 50 days of trading for this stock 2.57, while it was recorded at 3.39 for the last single week of trading, and 1.99 for the last 200 days.
Idera Pharmaceuticals Inc. [IDRA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Idera Pharmaceuticals Inc. [IDRA] shares currently have an operating margin of -3168.92. Idera Pharmaceuticals Inc.’s Net Margin is presently recorded at -3902.97.
Return on Total Capital for IDRA is now -170.30, given the latest momentum, and Return on Invested Capital for the company is -210.39. Return on Equity for this stock declined to -213.97, with Return on Assets sitting at -93.79.
Reflecting on the efficiency of the workforce at the company, Idera Pharmaceuticals Inc. [IDRA] managed to generate an average of -$1,569,861 per employee.Idera Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.60.
Earnings analysis for Idera Pharmaceuticals Inc. [IDRA]
With the latest financial reports released by the company, Idera Pharmaceuticals Inc. posted -1.76/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -402.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IDRA.
Insider trade positions for Idera Pharmaceuticals Inc. [IDRA]
There are presently around $38 million, or 25.20% of IDRA stock, in the hands of institutional investors. The top three institutional holders of IDRA stocks are: BAKER BROS. ADVISORS LP with ownership of 4,608,786, which is approximately 0% of the company’s market cap and around 0.70% of the total institutional ownership; VANGUARD GROUP INC, holding 967,577 shares of the stock with an approximate value of $4.12 million in IDRA stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $4.09 million in IDRA stock with ownership of nearly -7.008% of the company’s market capitalization.
Positions in Idera Pharmaceuticals Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 16 institutional holders increased their position in Idera Pharmaceuticals Inc. [NASDAQ:IDRA] by around 603,615 shares. Additionally, 22 investors decreased positions by around 795,818 shares, while 14 investors held positions by with 7,444,423 shares. The mentioned changes placed institutional holdings at 8,843,856 shares, according to the latest SEC report filing. IDRA stock had 4 new institutional investments in for a total of 338,144 shares, while 9 institutional investors sold positions of 299,468 shares during the same period.